%D9%87%D9%8A%D9%85%D9%88%D9%81%D9%8A%D9%84%D9%8A%D8%A7_%D8%A8Hemofiliya_BCategory:Hemophilia_BHaemophilia_BHemofilia_B%D9%87%D9%85%D9%88%D9%81%DB%8C%D9%84%DB%8C_%D8%A8%DB%8CEmofilia_B%E8%A1%80%E5%8F%8B%E7%97%85BChoroba_ChristmasaHemofilia_B%D0%93%D0%B5%D0%BC%D0%BE%D1%84%D0%B8%D0%BB%D0%B8%D1%8F_B%E0%B8%AE%E0%B8%B5%E0%B9%82%E0%B8%A1%E0%B8%9F%E0%B8%B4%E0%B9%80%E0%B8%A5%E0%B8%B5%E0%B8%A2_%E0%B8%9A%E0%B8%B5Hemofili_BQ2562598
about
Alexei Nikolaevich, Tsarevich of RussiaATHN 7: Hemophilia Natural History StudyPersonalized Medicine for Canadians With HemophiliaImpact of Conservative Treatment by Custom-made Orthoses in Patients With Haemophilic Ankle ArthropathyHaemophilia Patients With Inhibitors Being Treated for Acute Joint BleedsPost Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia BStudy Comparing On-Demand Treatment With Two Prophylaxis Regimens Of BeneFIX In Patients With Severe Hemophilia BSafety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B.Socialization of Adult Men With Congenital Hemophilia A or BBAX 326 Surgery Study in Hemophilia B PatientsEpidemiological Study on Haemophilia Care and Orthopaedic Status in Developing CountriesOsteoporosis and MRI Study in HemophiliaStudy Evaluating On-Demand Treatment With BeneFIX In Chinese SubjectsA Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in FranceAdverse Event Data Collection From External Registries on Nonacog Beta PegolA Study of Haemophilia B Patients Who Have Undergone Gene TherapyTrial of NovoSeven® in Haemophilia - Joint BleedsEfficacy of NovoSeven® in Bleeding Prophylaxis in HemophiliaA Study to Assess Pharmacokinetics and Pharmacodynamics Following Administration of BAY1093884 in Patients With Severe HemophiliaWeb Accessible Population Pharmacokinetics Service - Hemophilia: Sources of VariabilityVirtual Reality for HemophiliaSafety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy VolunteersPharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding StateIntra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding StatePrediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of ThromboelastographyBioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male SubjectsSafety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major SurgeryA Safety and Efficacy Study of a Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) in Patients With Hemophilia BLong-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia BStudy of Recombinant Coagulation Factor IX Fc Fusion Protein, BIIB029, in Previously Treated Pediatric Participants With Hemophilia BA Safety and Efficacy Study of a Recombinant Factor IX in Patients With Severe Hemophilia BSurvey Evaluating the Psychosocial Effects of Living With HaemophiliaStudy To Compare On-Demand Treatment To A Prophylaxis Regimen Of BeneFIX In Subjects With Moderately Severe to Severe Hemophilia BObservational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and InhibitorsSafety and Pharmacokinetic Study of a Recombinant Coagulation Factor IX Albumin Fusion Protein in Subjects With Hemophilia BRIXUBIS PMS India (RIXUBIS PMS)Study of Coagulation Factor VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia A and BAwareness, Care, and Treatment In Obesity Management of Patients With Hemophilia (ACTION) to Inform Hemophilia Obesity Patient Empowerment (HOPE)A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients Without InhibitorsA Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
P1050
Role of the vector genome and underlying factor IX mutation in immune responses to AAV gene therapy for hemophilia BX-ray structure of clotting factor IXa: active site and module structure related to Xase activity and hemophilia BErythroid-specific human factor IX delivery from in vivo selected hematopoietic stem cells following nonmyeloablative conditioning in hemophilia B miceTransforming the treatment for hemophilia B patients: update on the clinical development of recombinant fusion protein linking recombinant coagulation factor IX with recombinant albumin (rIX-FP)New developments in the management of moderate-to-severe hemophilia BDevelopments in the treatment of hemophilia B: focus on emerging gene therapyOnce-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BGene therapy in an era of emerging treatment options for hemophilia BHierarchical scaffold design for mesenchymal stem cell-based gene therapy of hemophilia BTreatment for haemophilia by postcodeSuccessful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune responseCharacterization of the mutations causing hemophilia B in 2 domestic cats.Insight into molecular changes of the FIX protein in a series of Italian patients with haemophilia B.Comprehensive analysis of phenotypes and genetics in 21 Chinese families with haemophilia B: characterization of five novel mutations.An interactive mutation database for human coagulation factor IX provides novel insights into the phenotypes and genetics of hemophilia B.Lithuanian haemophilia A and B registry comprising phenotypic and genotypic data.Prevalent inhibitors in haemophilia B subjects enrolled in the Universal Data Collection database.Translational Data from AAV-Mediated Gene Therapy of Hemophilia B in Dogs.Translational data from adeno-associated virus-mediated gene therapy of hemophilia B in dogs[Screening for carrier state of Haemophilia B using indirect genomic detection]Off-pump myocardial revascularization in a diabetic patient with severe hemophilia B and impaired left ventricular function: hematological and operative strategies.A gene-deleted adenoviral vector results in phenotypic correction of canine hemophilia B without liver toxicity or thrombocytopenia.Herpes simplex virus type 1 and human immunodeficiency virus type 1 antigens in platelets from a hemophilia B patient with human immunodeficiency virus type 1-related thrombocytopenia.Hemophilia A and B.AIDS-related thrombocytopenia. Experience of a medium-term treatment with intravenous IgG in haemophilia B patients.Molecular pathology of haemophilia BNational haemophilia B molecular genetic register.A new strategy for the genetic counselling of diseases of marked mutational heterogeneity: haemophilia B as a modelGenetic counselling in haemophilia by discriminant analysis 1975-1980Application of an intragenic genomic probe to genetic counselling for haemophilia B in the west of ScotlandApplication of three intragenic DNA polymorphisms for carrier detection in haemophilia B.Prenatal diagnosis of haemophilia B in the first trimesterCarrier detection through the use of abnormal deletion junction fragments in a case of haemophilia B involving complete deletion of the factor IX gene.Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of hemophilia B.Region of factor IXa protease domain that interacts with factor VIIIa: analysis of select hemophilia B mutants.Adeno-associated virus-mediated gene transfer of factor IX for treatment of hemophilia B by gene therapy.Gene therapy for hemophilia A and B: patient selection and follow-up, requirements for a cure.Spontaneous intracranial hemorrhage as the presenting sign of hemophilia B in a 3-month-old infant.Bioengineered factor IX molecules with increased catalytic activity improve the therapeutic index of gene therapy vectors for hemophilia BCRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice.
P921
Q154045-3f9347b6-4f37-5319-c624-10784c1ca684Q61902741-933C1B7A-BB9F-4E4E-ADA7-1FBC59580259Q61904956-547D78D4-C6AF-4AA3-B4F3-E5B06D6575B9Q61915179-909A2F78-4747-48E7-8C10-AB47B0189F15Q61918440-22128D99-66D7-4946-A5C7-43A391240955Q61918623-7E24222E-01C8-4A02-A3C4-91B3BCD5112FQ61934548-0668E5AF-A378-4EBB-ADA0-D32DE6291C2AQ61956183-59D9FCB1-274F-42EA-B338-219DD004144DQ61956198-EF6AEE6D-2ABD-40B5-885D-6354B22409EEQ61956668-5F1EF29A-157F-412D-B128-95E4F04F7F1FQ61957397-D1EBAAC8-C23D-4E9E-BF6F-A0BF861CA640Q61965727-85341E5C-12F8-4CB4-8092-13B15111758CQ61980975-A55A405A-8C72-4BF1-9132-87588B66F3F7Q62024990-0FC9C21F-F9B9-4B57-A143-3FF6348D28C8Q62054174-9C9EED29-8516-41DC-A708-C9B67BC7046FQ62062843-DBF62BD5-B9A9-469C-B35C-F0D239ECF944Q62105420-F747F597-B938-4670-9456-53679858299CQ62105423-FE6DCF39-3DEE-4C92-B926-FE5B3B2CBEF1Q62810969-B092E37F-45CF-482D-9532-2BF4E4ADD5ACQ62815287-A16CD63C-9C04-4C96-B0D5-09373BCD1832Q62822438-D05680EB-0F88-49EC-AF89-FF7A5DF61352Q63316002-396E7591-1909-49C1-9BAB-6B2CDBE443F6Q63316140-FEA9E958-A697-4219-B9FC-EA97622FB4A7Q63316161-83253833-5375-404B-BCCB-954DB0FC0F9EQ63316287-167DE2F3-0EA7-4393-ACC2-9E64DCF6D991Q63316407-03C7B855-E4EF-420C-9004-CB56FDBB9B99Q63316415-4DD07CBE-B95C-4DF7-9B50-9F0E8C33EB7AQ63319159-9AD96E94-1A9C-49E2-8F94-CF3F55C51058Q63321289-3E7891FA-6700-4CE8-BB38-09C31CE47628Q63322409-EDAE646F-0C16-42E0-A92F-3F9DC4781030Q63335259-BA678670-108B-4E6A-A372-F737FFF6F6BBQ63335829-A24A4BB7-7E1B-45D7-B3DA-129FFA600A99Q63336298-67378FAD-649A-4DAA-B947-C7F2C7156C31Q63340824-4F139EAC-9697-476B-8742-101184AC5684Q63340917-63578E4B-4E7C-47BA-8769-F11B7A370A1AQ63398631-F015EDD3-A1AA-4003-A64E-068B6989CF03Q63403848-1237FEC9-78F9-40A9-BD3E-3411114D315BQ63404339-3EB84FB6-4D4E-41BF-A523-7F5CC497BEB2Q63404492-B9BF322D-7A5B-402C-8BEE-D82DA2236CA7Q63404540-EDB2ABC3-B354-4263-A831-0C6105A0C6D2
P1050
description
An inherited blood coagulation ...... s an X-linked recessive trait.
@en
Krankheit
@de
disturbo della coagulazione ca ...... fattore IX della coagulazione
@it
kanın pıhtılaşması için gerekl ...... ıyla ortaya çıkan bir hastalık
@tr
maladie
@fr
name
B형혈우병
@ko
Choroba Christmasa
@pl
Hemofili B
@tr
Hemofilia B
@pt
Hemofiliya B
@az
emofilia B
@it
hemofilia B
@es
hemofilio B
@eo
hemophilia B
@en
hémophilie B
@fr
type
label
B형혈우병
@ko
Choroba Christmasa
@pl
Hemofili B
@tr
Hemofilia B
@pt
Hemofiliya B
@az
emofilia B
@it
hemofilia B
@es
hemofilio B
@eo
hemophilia B
@en
hémophilie B
@fr
altLabel
Christmas disease
@en
Congenital factor IX deficiency
@en
Congenital factor IX disorder
@en
Doença de Christmas
@pt
Enfermedad de Christmas
@es
Factor IX deficiency
@en
Hemofilia B
@pl
Hemophilia B (disorder)
@en
deficiency, functional factor IX
@en
factor IX deficiency
@en
prefLabel
B형혈우병
@ko
Choroba Christmasa
@pl
Hemofili B
@tr
Hemofilia B
@pt
Hemofiliya B
@az
emofilia B
@it
hemofilia B
@es
hemofilio B
@eo
hemophilia B
@en
hémophilie B
@fr
P279
P672
P486
P6366
P646
P1199
P1417
science/hemophilia-B
P1461
haemophilia-b-factor-ix-deficiency
P1692
P1748
P1995
P2888
P2892
P31
P3417
Hemophilia-B
P373
Hemophilia B
P3827
hemophilia-b